Equities

Rohto Pharmaceutical Co Ltd

Rohto Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,411.00
  • Today's Change28.00 / 0.83%
  • Shares traded370.80k
  • 1 Year change-4.80%
  • Beta0.3264
Data delayed at least 20 minutes, as of Nov 11 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ROHTO PHARMACEUTICAL CO., LTD. is a Japan-based company principally engaged in the health and beauty care area. The Company primarily provides eye care-related products, including eye drops and eye lotions; skin care-related products, including dermatological preparations, lip balms, sunscreens and functional cosmetics; oral medication and food-related products, including digestive medicines, Chinese herbal medicines and supplements, as well as extracorporeal test drugs and other products. The Company operates its business in domestic market and overseas markets, including Europe, Asia and America.

  • Revenue in JPY (TTM)278.03bn
  • Net income in JPY30.33bn
  • Incorporated1949
  • Employees7.26k
  • Location
    Rohto Pharmaceutical Co Ltd1-8-1, Tatsumi-Nishi, Ikuno-kuOSAKA-SHI 544-8666JapanJPN
  • Phone+81 667581231
  • Websitehttps://www.rohto.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Towa Pharmaceutical Co Ltd235.95bn16.92bn161.76bn4.59k9.140.94824.590.6856343.72343.724,793.823,311.490.55821.493.6051,428,070.004.004.214.915.6335.9039.237.177.231.62--0.566621.019.1316.74634.803.7228.2010.86
KAKEN PHARMACEUTICAL CO., LTD.87.25bn18.24bn177.74bn1.14k8.030.9498.512.04481.71481.712,303.804,076.800.48641.983.8876,867,840.0010.176.8311.667.8760.6654.7820.9114.484.47--0.024351.25-1.29-5.2147.52-14.700.36390.00
Kissei Pharmaceutical Co Ltd81.07bn10.73bn180.48bn1.78k15.140.736611.822.23241.71241.711,825.834,969.030.32941.602.9845,568,860.004.383.614.753.9049.8849.4713.3112.694.15--0.005734.8711.980.89196.0015.286.5810.40
Sumitomo Pharma Co Ltd342.67bn-279.46bn233.57bn4.98k--2.04--0.6816-703.41-703.41862.50287.370.35171.304.2868,808,230.00-28.68-5.07-51.21-7.7359.5669.99-81.54-12.280.424-12.100.7732---43.38-7.29-322.71--4.02--
Sawai Group Holdings Co Ltd178.04bn17.78bn259.19bn3.48k14.611.218.581.46134.98194.991,352.921,627.680.46711.172.8351,130,670.003.480.71044.620.970531.1435.087.441.471.5843.190.292788.138.04-0.824946.82-2.3318.150.00
Nippon Shinyaku Co., Ltd.150.37bn27.37bn287.89bn2.21k10.091.228.831.91406.30406.302,232.623,372.500.59761.373.2067,949,390.0010.8810.4512.4112.3166.8161.2718.2016.473.73--0.011432.622.835.2613.329.6645.9312.12
Tsumura & Co164.61bn25.20bn367.83bn4.14k14.441.249.602.23331.93331.932,167.873,875.470.37830.69162.4839,781,050.006.234.817.635.8948.7650.9816.4812.653.04--0.180632.167.714.521.372.7417.545.84
Hisamitsu Pharmaceutical Co Inc150.19bn14.65bn372.43bn2.76k22.401.1717.862.48195.20195.201,996.173,730.090.43233.013.2254,434,580.004.364.225.254.8256.4258.6210.1010.033.14--0.00453.0510.42-0.238518.97-6.1728.900.5989
Santen Pharmaceutical Co Ltd302.56bn26.12bn638.31bn3.74k23.892.1214.372.1173.4073.40845.69827.650.72382.583.6880,812,770.006.253.317.774.1057.9259.738.645.211.975.380.163982.218.225.23278.09-3.585.104.88
Rohto Pharmaceutical Co Ltd278.03bn30.33bn798.99bn7.26k25.522.9920.202.87132.56132.561,215.221,129.950.76422.214.3738,300,730.008.428.5411.7011.7957.7658.5911.0210.301.27--0.151319.3913.488.0917.2825.855.2018.61
Ono Pharmaceutical Co Ltd484.30bn95.13bn950.01bn3.85k9.471.148.391.96201.26201.261,026.051,665.850.49872.373.47125,694,000.009.8011.9511.1613.7375.3874.1119.6523.892.80--0.170232.2512.4111.7313.5319.95-6.7912.20
Kyowa Kirin Co Ltd498.98bn83.53bn1.37tn5.97k16.691.6412.732.75156.64156.64936.101,591.790.48781.783.9283,524,780.008.176.289.507.0874.3075.4516.7414.963.06--0.027647.2511.0110.2551.5510.5210.289.86
Eisai Co Ltd753.22bn40.97bn1.51tn11.07k35.411.7518.232.00143.36143.362,634.812,905.110.56730.89333.8968,060,180.003.215.294.327.1679.1276.915.678.681.50--0.178174.13-0.35612.90-23.50-7.72-2.111.30
Data as of Nov 11 2024. Currency figures normalised to Rohto Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

25.39%Per cent of shares held by top holders
HolderShares% Held
MFS International (UK) Ltd.as of 30 Sep 202412.95m5.48%
SPARX Asset Management Co., Ltd.as of 15 Feb 202311.71m4.96%
Fidelity Management & Research Co. LLCas of 30 Sep 20247.23m3.06%
Nomura Asset Management Co., Ltd.as of 03 Oct 20246.66m2.82%
The Vanguard Group, Inc.as of 02 Oct 20246.53m2.76%
Norges Bank Investment Managementas of 30 Jun 20243.65m1.55%
Nikko Asset Management Co., Ltd.as of 04 Oct 20243.07m1.30%
Daiwa Asset Management Co. Ltd.as of 30 Sep 20243.05m1.29%
Artisan Partners LPas of 30 Sep 20242.73m1.16%
FIL Investments (Japan) Ltd.as of 30 Sep 20242.39m1.01%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.